Chair(s): Dorina Rama Esendagli, Peter Jaksch, Francesco Blasi
Session type: Hot topics
Cl?mence Martin
Session content
Is cystic fibrosis still an indication for lung transplantation?
Cl?mence Martin
Replay
Slides
Tamara Vagg
Replay
Slides
Alberto Benazzo
Replay
Slides
Christian Benden
Replay
Slides
Replay
Session aims
To discuss how the landscape of therapies and lung transplantation in cystic fibrosis (CF) has changed in the last year, covering the marked drop in lung transplant referrals due to the introduction of CF transmembrane conductance regulator modulator therapies; the change in the phenotype of CF lung transplant candidates, who are now older, have more complex multi-drug-resistant colonisations and more severe extra-respiratory comorbidities and sometimes need multi-organ transplantation; challenges in post-transplant management including the use of modulator therapies after transplant; and the use of artificial intelligence in patient phenotyping.